A Smo/Gli Multitarget Hedgehog Pathway Inhibitor Impairs Tumor Growth

Pharmacological Hedgehog (Hh) pathway inhibition has emerged as a valuable anticancer strategy. A number of small molecules able to block the pathway at the upstream receptor Smoothened (Smo) or the downstream effector glioma-associated oncogene 1 (Gli1) has been designed and developed. In a recent...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancers (Basel)
Autores principales: Lospinoso Severini, Ludovica, Quaglio, Deborah, Basili, Irene, Ghirga, Francesca, Bufalieri, Francesca, Caimano, Miriam, Balducci, Silvia, Moretti, Marta, Romeo, Isabella, Loricchio, Elena, Maroder, Marella, Botta, Bruno, Mori, Mattia, Infante, Paola, Di Marcotullio, Lucia
Formato: Artigo
Lenguaje:Inglês
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6826940/
https://ncbi.nlm.nih.gov/pubmed/31601026
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11101518
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares